Cuthbertson, Daniel J. http://orcid.org/0000-0002-6128-0822
Wilding, John P. H.
Article History
First Online: 16 July 2021
Competing interests
: D.J.C. has received funding for investigator-initiated studies from AstraZeneca, Novo Nordisk, Pfizer, Ipsen and Boehringer Ingelheim and educational grants from Janssen Pharmaceuticals, Lilly and Sanofi. J.P.H.W. has acted as a consultant, received institutional grants, and given lectures on behalf of pharmaceutical companies developing or marketing medicines used for the treatment of diabetes and obesity, specifically Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Mundipharma, Napp, Novo Nordisk, Orexigen, Rhythm Pharmaceuticals, Sanofi and Takeda, and Wilmington Healthcare.